You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS can be administered in an outpatient setting for appropriate patients1,2

Patient factors to consider for outpatient administration with VYXEOS

1

Deemed stable by
medical team3-5

  • ECOG performance status 0-1 and no significant comorbidities such as kidney or pulmonary diseases or active uncontrolled infections
2

Capable of self-care activities3,5

  • Ability to consistently attend all scheduled visits and participate in self-care activities such as taking temperature
3

In close proximity to their infusion center/cancer center3,5

  • Ability to consistently attend all scheduled visits for treatment and monitoring
  • Ability to attend necessary visits for supportive care such as blood transfusions

Institutional factors to consider for outpatient administration with VYXEOS

1

Timely access to supportive care that may include3,5

  • Blood and platelet transfusion support
  • Prophylactic antimicrobial implementation
2

A multidisciplinary team that can3,5

  • Coordinate and manage expectations for outpatient care with the patient
  • Assess and evaluate lab results
  • Monitor symptoms, side effects, and/or signs of toxicity
3

Inpatient access that allows for3

  • Unplanned admission due to persistent fever or urgent adverse events
Doctor

“Successful implementation of an outpatient approach requires that patients have quick, easy access to providers.”5

– Treating hematologist

Learn more about induction, consolidation, and outpatient administration with VYXEOS

Download PDF

Explore an expansive video library, where experts discuss outpatient use of VYXEOS

Watch videos

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.